Skip to Main Content

View Public Comments for Positron Emission Tomography

Use the browser below to select the Comment Period for which you would like to view the comments for the selected document. You can use the alphabetical links above the results table to jump to comments submitted by a commenter whose last name starts with that letter. Select the ‘Expand All Comments’ link to view all the full comments, and click the ‘Collapse All Comments’ link to view only the abstract for all comments. Select the ‘More’ link in the Comment to view the full text of the specific comment in a new window.
The first (earliest) set of comments are displayed by default in the Public Comment Results section. To view additional Comment Periods, use the radio button options and select the "Submit" button.
An asterisk (*) indicates a required field.

      Select one period.



[26 Comments]
Page 1 of 2
FirstPrev12NextLast
First character of titleCommenterComment Information
A
Allen, Gregg P. Title: Chief Medical Officer
Organization: MedSolutions, Inc.
Date: 07/20/2012
Comment:

This proposed amendment has the potential for significant expansion of PET without a definite corresponding level of increased patient benefits. Coverage based purely on FDA approval would be a remarkable departure from the previously successful More opens in new window

A
Asay, Derek Title: Director, Govt Strategy, Fed Accts and Quality
Organization: Lilly USA LLC
Date: 08/07/2012
Comment:

Re: National Coverage Analysis (NCA) Tracking Sheet for Positron Emission Tomography (CAG-00065R2)

Dear Dr. Roche and Mr. Caplan:

On behalf of Lilly USA, LLC, we appreciate the opportunity to submit public More opens in new window

B
Bocchino, Carmella Title: EVP, Clinical Affairs and Strategic Planning
Organization: America's Health Insurance Plans (AHIP)
Date: 08/10/2012
Comment:

Stuart Caplan RN, MAS
Lead Analyst
Centers for Medicare and Medicaid Services
Mail Stop C1-09-06
7500 Security Boulevard
Baltimore, Maryland 21244-1850

Dear Mr. Caplan:

Thank you for the More opens in new window

B
Bunning, Sue Title: Director, Health Policy & Regulatory Affairs
Organization: Society of Nuclear Medicine and Molecular Imaging
Date: 08/10/2012
Comment:

THE FOLLOWING COMMENTS WILL ALSO BE SUBMITTED AS AN ATTACHMENT TO CAGInquiries@CMS.HHS.GOV

Re: National Coverage Analysis Reconsideration Request for Positron Emission Tomography (CAG-00065R2)

Dear Dr. Jacques:

The More opens in new window

C
Czernin, Johannes Organization: UCLA Medical Center
Date: 08/10/2012
Comment:

Dear Dr. Roche and Mr. Caplan:

As a practicing clinician with two decades of experience working with advanced imaging technologies, I write in strong support of lifting the national non-coverage language for new FDA approved PET More opens in new window

D
Delpassand, M.D., Ebrahim Title: Chairman and Medical Director
Organization: Excel Diagnostics and Nuclear Oncology Center
Date: 07/13/2012
Comment:

Considering the curent vigorous evaluation of new PET radiopharmaceuticals by FDA, whcih is one of the federal Government agencies like CMS, these agencies need to communicate and collaborate together and immediate coverage should be issued at More opens in new window

D
Dinkelborg, PhD, Ludger Title: Managing Director
Organization: Piramal Imaging GmbH
Date: 08/10/2012
Comment:

August 10, 2012

Jeffrey Roche, MD, MPH
Lead Medical Officer
Centers for Medicare and Medicaid Services
Coverage Analysis Group
7500 Security Boulevard
Baltimore, MD 21244

Stuart Caplan, More opens in new window
D
Djang, David Title: Physician
Organization: Seattle Nuclear Medicine
Date: 07/30/2012
Comment:

I am a nuclear medicine physician. The approval mechanism for PET tracers is far too slow. Patients and clinicians sometimes call me, frustrated, that there is a very promising tracer for their disease, often studied and published in the More opens in new window

D
Duffy, Michael P. Title: Vice President and General Counsel
Organization: Lantheus Medical Imaging
Date: 07/28/2012
Comment:

Lantheus Medical Imaging, Inc. (“Lantheus”) appreciates the opportunity to submit comments to the Centers for Medicare and Medicaid Services (“CMS”) regarding the National Coverage Analysis for Positron Emission Tomography (CAG-00065R2). We More opens in new window

E
Egge, Robert Title: Vice President, Public Policy
Organization: Alzheimer's Association
Date: 08/10/2012
Comment:

Jeffrey Roche MD, MPH
Stuart Caplan RN, MAS
Centers for Medicare & Medicaid Services
7500 Security Boulevard
Bethesda, MD 21244

Re: National Coverage Analysis Reconsideration Request for Positron Emission More opens in new window

F
Frank, Richard Title: Vice President, Global Clinical Strategy and Polic
Organization: GEHC
Date: 08/09/2012
Comment:

GE Healthcare
1299 Pennsylvania Ave, NW
Suite 900W
Washington, DC 20004

August 9, 2012
Jeffrey Roche MD, MPH
Lead Medical Officer
Stuart Kaplan, RN, MAS
Lead Analyst
Coverage and More opens in new window

F
Frassine, Harald Date: 08/08/2012
Comment:
Please consider F-18 NaF at least as a bone scanning agent for the extremely obese, exactly for the same reasons Rb-82 RbCl and N-13 NH3 are generally accepted for myocardial perfusion testing in the obese f.e. by Aetna and Anthem, see More opens in new window
G
Gelovani, Juri Title: President
Organization: World Molecular Imaging Society
Date: 08/08/2012
Comment:
August 8th, 2012
Louis Jacques, MD
Director, Coverage and Analysis Group
Centers for Medicare & Medicaid Services
7500 Security Blvd., Mail Stop C1-09-06
Baltimore, MD 21244

Re: National Coverage More opens in new window

H
Hubner, Karl Title: Professor Emeritus, Radiology
Organization: UT Medical Center
Date: 08/10/2012
Comment:

I have experienced the development of PET imaging in its early research state at the Medical Division of ORAU in Oak Ridge, TN in the mid-1970s, and have been involved in establishing one of the first clinical PET centers in the U.S. at the UT More opens in new window

K
Kolb, PhD, Hartmuth Title: Vice President
Organization: Siemens Molecular Imaging Biomarker Research
Date: 08/09/2012
Comment:

August 9, 2012

RE: National Coverage Analysis for Positron Emission Tomography (CAG-00065R2)

Dear Dr. Roche and Mr. Caplan:

Siemens Molecular Imaging Biomarker Research (MIBR) thanks the Centers for Medicare and More opens in new window

K
Kovach, MD, George Title: President
Organization: Association of Community Cancer Centers
Date: 08/09/2012
Comment:

August 9, 2012

BY ELECTRONIC DELIVERY

Jeffrey Roche, MD, MPH
Lead Medical Officer

Stuart Caplan, RN, MAS
Lead Analyst

Centers for Medicare and Medicaid More opens in new window

L
Lynch, MD, Mike Date: 07/25/2012
Comment:

We encourage CMS to require high quality evidence that supports superior results from PET scanning when compared to other less costly imaging. Required evidence or results should go beyond a determination that the imaging is non-inferior. More opens in new window

N
Naqvi, Al Title: President
Organization: PlanClear Company
Date: 08/10/2012
Comment:

August 10th, 2012

Re: National Coverage Analysis (NCA) Tracking Sheet for Positron Emission Tomography (CAG-00065R2)

Dear Dear Dr. Roche and Mr. Caplan:

We provide content, analysis, and studies for the molecular More opens in new window

N
Nathan, MD, Mark Title: Chair, Division of Nuclear Medicine
Organization: Mayo Clinic
Date: 08/08/2012
Comment:

Jeffrey Roche MD, MPH
Centers for Medicare & Medicaid Services
7500 Security Boulevard,
Baltimore, MD 21244

Dear Dr. Roche:

We appreciate this opportunity to submit comments to the Centers for Medicare & More opens in new window

N
Novich, Ira Title: Medical director
Organization: Carecore National
Date: 07/12/2012
Comment:

Policy regarding the use of PET technology should be made at the national level. Policies regarding the use of any procedure or technology should be based on rigorous scientific evidence published and scrutinized in peer reviewed journals. There More opens in new window

P
Pracht, Laurel Title: Patient Advocate
Organization: Society of Nuclear Medicine and Molecular Imaging
Date: 07/13/2012
Comment:

Removal of the exclusionary language is an appropriate decision utilizing radiotracers currently FDA approved along with future tracers bearing FDA approval for PET scans.

I urge you, on behalf of patients who benefit from PET scans More opens in new window

R
Rademacher, John Title: President, Nuclear Pharmacy Services
Organization: Cardinal Health
Date: 08/10/2012
Comment:

Cardinal Health is pleased to respond to the Centers for Medicaid and Medicare Services (CMS) request for comments on the reconsideration request of Section 220.6 of the National Coverage Determinations (NCD) Manual, dealing with Positron More opens in new window

R
Rodriguez, Gail Title: Executive Director
Organization: MITA
Date: 08/02/2012
Comment:

THE FOLLOWING COMMENTS WILL ALSO BE SUBMITTED AS AN ATTACHEMENT TO CAGInquiries@CMS.HHS.GOV.

Re: National Coverage Analysis Reconsideration Request for Positron Emission Tomography (CAG-00065R2)

Dear Dr. More opens in new window

V
Vazquez, Elliot Title: Administrator
Organization: Jefferson Outpatient Imaging
Date: 08/07/2012
Comment:

Removal of the exclusionary language is an appropriate decision utilizing radiotracers currently FDA approved along with future tracers bearing FDA approval for PET scans. I urge you, on behalf of patients who benefit from PET scans using More opens in new window

V
Vradenburg, George Title: Chairman
Organization: USAgainstAlzheimer's
Date: 08/08/2012
Comment:

Dear Dr. Roche and Ms. Kaplan:

USAgainstAlzheimer's, the national mobilization network committed to stopping Alzheimer's disease by 2020, encourages the Centers for Medicare & Medicaid Services (CMS) to remove the blanket national More opens in new window

Page 1 of 2
FirstPrev12NextLast
50